CLGN - CollPlant Ltd Price-to-Projected Revenue Ratio
The primary driver for CollPlant Biotechnologies (CLGN) is its monopoly right to rhCollagen produced in tobacco. The forward P/S trend on the GURU.Markets terminal chart confirms this, where the 27.20 mark serves as the current indicator. Revenues are based on the supply of biomaterials for organ 3D printing and cosmetology. High B2B confidence from global corporations in the company's regenerative technologies opens significant growth prospects.
collplant.com - analytical breakdowns and key metrics (CLGN)
- market price and analyst price targets:
- market capitalization statistics:
- book value of equity indicators:
- debt burden and liquidity indicators:
Debt to Equity CollPlant Biotechnologies|CLGN - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio CollPlant Biotechnologies Ltd.|CLGN - Company Cumulative Indebtedness|Debt to Book Value CLGN|CLGN - Company Long-Term Loans and Borrowings|Company Short-Term Debts CollPlant Biotechnologies|Quick Ratio collplant.com
- business earnings and investment ratios data:
CLGN - Net Financial Result|Expected Profit CollPlant Biotechnologies|CLGN - Market Cap to Earnings|Projected Price to Earnings CollPlant Biotechnologies Ltd.|CLGN - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple CLGN|CLGN - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) CollPlant Biotechnologies|CLGN - Net earnings per share for the last 12 months|Quarterly EPS earnings growth collplant.com|CLGN - Earnings per share increase in current year|Net earnings per share growth forecast for next year CollPlant Biotechnologies
- sales revenue and business income indicators:
General company analysis:CollPlant Ltd (CLGN)
CollPlant Biotechnologies leads the regenerative medicine segment by creating innovative bio-inks from plant-based collagen. The company's forward P/S trend reflects the market value of the business relative to expected revenue, allowing investors to assess the asset's degree of overheating or its growth potential based on current sales forecasts and current share prices.
Key competitors
Price-to-Projected Revenue Ratio HCA Healthcare HCA|Tenet Healthcare Corp - Price-to-Projected Revenue Ratio|FMS - Price-to-Projected Revenue Ratio|Future Price to Revenue SOLV|Encompass Health (EHC) - Price-to-Projected Revenue Ratio|UHS (Universal Health Services, Inc.) - Price-to-Projected Revenue Ratio|DVA (DaVita) - Forward P/S Multiple|Forward P/S Multiple RadNet Inc|Price-to-Projected Revenue Ratio Option Care Health Inc (OPCH)|Surgery Partners Group - Market Cap to Projected Revenue|Premier, Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio EYE (nationalvision.com)|PGNY: Forward Price-to-Revenue Multiple|Forward Price to Sales ARDT (Ardent Health)|SEM: Forward P/S Multiple|ASTH (Astrana Corp) - Price-to-Projected Revenue Ratio|MD (Pediatrix Corp) - Forward P/S Multiple|US Physical Therapy Inc (USPH) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio The Pennant Group (PNTG)|ORGO - Market Cap to Future Revenue Ratio|Nutex Health Corp - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio AUNA (Auna Corp)|SBC Medical Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio evolus.com|CYH: Forward P/S Multiple|Forward Price-to-Revenue Multiple BeautyHealth|MDWD (MediWound Ltd) - Forward P/S Multiple|BTMD: Forward Price to Sales|Price-to-Projected Revenue Ratio The Joint Corp. (JYNT)|docgo.com - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio P3 Health Partners PIII|Gain Therapeutics Inc. (GANX) - Market Cap to Future Revenue Ratio|EUDA - Price-to-Projected Revenue Ratio|BMGL: Price-to-Projected Revenue Ratio|Cuprina Holdings (Cayman) Ltd (CUPR) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio concordmedical.com (CCM)|AMS (American Shared Hospital Services) - Forward P/S Multiple|MRM - Projected Price to Revenue|Forward P/S Multiple ALBT|Market Cap to Expected Sales Ratio DIH Group|Forward P/S Multiple XAGE (Longevity Health Holdings)|newgenivf.com (NIVF) - Market Cap to Future Revenue Ratio|ATIP - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio CareMax Inc. CMAX|KDLY: Forward P/S Multiple|Forward Price-to-Revenue Multiple ModivCare Corp|Price-to-Projected Revenue Ratio Novo Integrated Sciences|Price-to-Projected Revenue Ratio SSY|Forward P/S Multiple BACK
